Pascal Soriot, koncernchef, kommenterar resultatet: "Vi stärkte vår forskningsportfölj och levererade ett starkt finansiellt resultat under 2015 samtidigt som vi påbörjade nästa fas av vår strategiska resa. .....
Det första nya läkemedlet som godkänts inom ramen för Europeiska kommissionens accelererade process Godkännandet baseras på studier som visar på en objektiv responsfrekvens av 66 % och en progressionsfri överlevnad med en median på 9,7 månader. Tumörprov eller blodprov kan fastställa vilka patienter som sannolikt kan dra nytta av osimertinib
TAGRISSO™ is the first new medicine to be approved under the European Commission’s expedited process
Approval based on studies showing objective response rate of 66% and median progression-free survival of 9.7 months
Tumour sample or blood test can determine patients likely to benefit from osimertinib
AstraZeneca today announced that the European Commission (EC) has granted conditional m
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for the oral poly ADP-ribose polymerase (PARP) inhibitor Lynparza™ (olaparib),
AstraZeneca and Incyte Corporation today announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso® (osimertinib). The combination will be assessed as a second line treatment for patients with EGFR mutation-positive
Moderna to lead preclinical development; AstraZeneca to lead clinical development; Moderna to co-commercialise and share profits on resulting products in the US
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved ZURAMPIC®(lesinurad) 200mg tablets in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with gout
AstraZeneca meddelar idag att den europeiska läkemedelsmyndigheten EMA:s rådgivande kommitté CHMP ger positivt besked och rekommenderar godkännande av TAGRISSO™ (AZD9291, osimertinib) och lesinurad, samt ny indikation för BRILIQUE (ticagrelor) 60mg för behandling av patienter som har en historia av hjärtinfarkt och hög risk att få en ytterligare aterotrombotisk händelse.
Durvalumab demonstrated clinical activity and durable responses in 3rd-line or later stage NSCLC patients; full data to be presented at a scientific congress in 2016
Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor, acalabrutinib Opportunity for first regulatory submissions in haematological malignancies in 2016
Strategic alliance with WuXi AppTec to develop next-generation biologics in China New small molecule development facility; new global hub for Pharmaceutical Development
Acquisition to include non-US rights to roflumilast and will beaccretive to 2016 earnings, contributing to AstraZeneca’s return to growth strategy
Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.
The Company will make a further announcement if and when appropriate.
– ENDS –
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, inn
AstraZeneca och koncernens globala forsknings- och utvecklingsbolag för biologiska läkemedel, Medimmune, meddelar idag ett treårigt samarbete med det nybildade forskningscentret Wallenberg Centre for Protein Research (WCPR).
Divestmentfurther sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015
AstraZeneca and Sanofi today announced a direct exchange of 210,000 compounds from their respective proprietary compound libraries. The swap represents a novel open innovation model between pharmaceutical companies.
AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical
One of fastest development programmes – from start of clinical trials to approval in just over two and a half years to meet unmet patient need With objective response rate of 59% and duration of response of 12.4 months, TAGRISSO provides important new option for patients
BRO:s Utmärkelse 2015 tilldelas Helena Janlöv-Remnerud, sjuksköterska och medicinsk lymfterapeut, hemmahörande i Edsbro i Uppland.
Data presented at AHA suggests benefit in patients who stayed on Brilique (ticagrelor) treatment.